Erythropoietin in Acute Ischemic Stroke Management

Introduction to Erythropoietin Use

• The American Heart Association/American Stroke Association guidelines recommend against the use of erythropoietin (EPO) for the treatment of acute ischemic stroke due to increased mortality risk without demonstrated clinical benefit, particularly in patients receiving thrombolytic therapy 1

Evidence from Clinical Trials

• A small pilot trial showed a nonsignificant reduction in combined death and dependency with EPO 1
• Preliminary data from a pivotal trial demonstrated that EPO treatment increased mortality in acute stroke patients 1
• The guidelines conclude that considerable experimental and clinical research is required before any pharmaceutical agent with identified neuroprotective effects, including EPO, can be recommended for acute ischemic stroke treatment 1

Safety Concerns in Chronic Kidney Disease

• The TREAT study demonstrated a doubling of stroke risk with higher hemoglobin targets achieved through erythropoietin-stimulating agents compared to lower targets 2, 3
• Guideline recommendations target hemoglobin values between 100-120 g/L in CKD patients, not higher 2, 3

Clinical Management

• The American Heart Association/American Stroke Association recommends focusing on proven interventions: IV rtPA within 3-4.5 hours and/or mechanical thrombectomy within 6 hours for large vessel occlusion 1, 4